Zentalis Virtual WEE1 KOL Event

Virtual, September 24, 2020

Zentalis Pharmaceuticals (ZNTL) is hosting a Key Opinion Leader (KOL) virtual meeting on its WEE1 inhibitor clinical candidate ZN-c3, and its potential as a best-in-class treatment for advanced solid tumors on Thursday, September 24, 2020 from 12:00 p.m. to 1:30 p.m. ET.

The virtual event will feature presentations by KOL Kwok-Kin Wong, MD, PhD, Professor of Oncology, Department of Medicine at the NYU Grossman School of Medicine and Director of the Division of Hematology and Medical Oncology Chief at The Perlmutter Cancer Center at NYU Langone Medical Center and KOL Gordon Mills, MD, PhD, Professor of Cell, Developmental and Cancer Biology, School of Medicine and Director of Precision Oncology and SMMART Trials, Knight Cancer Institute at Oregon Health & Science University. The Zentalis management team will also provide an overview of the ongoing clinical development strategy of ZN-c3.

The inhibition of WEE1 aims to generate sufficient DNA damage to cancer cells, resulting in programmed cell death and prevention of tumor growth. ZN-c3 is designed to have a best-in-class product profile with significant advantages over other investigational WEE1 inhibitor therapies, including good solubility, target selectivity and pharmacokinetic properties. The Company is currently conducting a Phase 1/2 trial in patients with advanced solid tumors.

Date: Thursday, September 24th
Time: 12-1:30pm ET

 

Zentalis_Aug2020_vugbc4.jpg

RSVP for Event / Log Back in

Additional menu options can be found in the menu bar on the left or at the top.

Zentalis [ZNTL] US$1,116 MM MCap
In ad­di­tion to its lead pro­gram, ZN-c5, an oral SERD for es­tro­gen re­cep­tor pos­i­tive, HER2-neg­a­tive breast can­cer, the Com­pany is de­vel­op­ing a broad pipe­line of on­col­o­gy can­di­dates, tar­get­ing ar­eas of ma­jor un­met med­i­cal need. [more in­for­ma­tion]

Event Contact

Rebecca John
Solebury Trout